The Willet F. Whitmore, Jr., Lectureship: Blockade of Epidermal Growth Factor Receptors as Anticancer Therapy

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Apr 2001THE WILLET F. WHITMORE, JR., LECTURESHIP: BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTORS AS ANTICANCER THERAPY JOHN MENDELSOHN and COLIN P.N. DINNEY JOHN MENDELSOHNJOHN MENDELSOHN Financial interest and/or other relationships with ImClone Systems and Bristol Myers Squibb. More articles by this author and COLIN P.N. DINNEYCOLIN P.N. DINNEY Financial interest and/or other relationships with Bayer Pharmaceutical, Imclone Systems and Matrix Pharmaceutical. More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)66453-1AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail References 1 : Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A1983; 80: 1337. Google Scholar 2 : Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med1983; 1: 511. Google Scholar 3 : Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem1984; 259: 7755. Google Scholar 4 : Blockade of receptors for growth factors: an anti-cancer therapy. Clin Cancer Res2000; 6: 747. Google Scholar 5 : Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res1995; 1: 1311. Google Scholar 6 : Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res Treat1999; 55: 267. Google Scholar 7 : Growth stimulation by coexpression of transforming growth factor-alpha and epidermal growth factor receptor in normal and adenomatous human colon epithelium. J Clin Invest1990; 86: 356. Google Scholar 8 : Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest1995; 95: 1897. Google Scholar 9 : Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res1996; 56: 3666. Google Scholar 10 : A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem1982; 20: 149. Google Scholar 11 : Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene1996; 12: 1397. Google Scholar 12 : Reciprocal changes in p27KIP1 and p21CIP1 in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res1997; 3: 1943. Google Scholar 13 : Chimeric monoclonal antibody (Mab) C225 to the epidermal growth factor receptor (EGF-R) inhibits the growth of human transitional cell carcinoma (TCC) in the bladder of nude mice. Proc Annu Meet Am Assoc Cancer Res1997; 38: 1543. Google Scholar 14 : Nuclear targeting of Bax during epidermal growth factor receptor-induced apoptosis in colorectal cancer cells. Oncogene1998; 17: 999. Google Scholar 15 : Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res1999; 59: 1935. Google Scholar 16 : Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin Cancer Res1999; 5: 875. Google Scholar 17 : Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor α. Cancer Res1992; 52: 5887. Google Scholar 18 : Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res1993; 53: 4322. Google Scholar 19 : Epidermal growth factor receptor and bladder cancer: a review. Urol Int1992; 48: 365. Google Scholar 20 : Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res1997; 17: 1293. Google Scholar 21 : Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst1995; 87: 1603. Google Scholar 22 : Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol1993; 150: 1126. Link, Google Scholar 23 : Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst1993; 85: 241. Google Scholar 24 : Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. Cancer Res1997; 57: 136. Google Scholar 25 : Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res1995; 55: 510. Google Scholar 26 : Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res1996; 56: 4799. Google Scholar 27 : Expression of scatter factor in human bladder carcinoma. J Natl Cancer Inst1995; 87: 372. Google Scholar 28 : Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder. J Urol1997; 157: 72. Link, Google Scholar 29 : The angiogenic factor midline is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res1996; 56: 2515. Google Scholar 30 : Interleukin-8 expression and human bladder cancer: in situ and in vitro expression of IL-8 by human bladder cancer cells. J Urol1997; 157: 28. Google Scholar 31 : Transforming growth factors-B1 and B2 in serum and urine from patients with bladder carcinoma. J Urol1996; 156: 953. Link, Google Scholar 32 : Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol1998; 152: 591. Google Scholar 33 : Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J Urol1997; 157: 2351. Link, Google Scholar 34 : Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol1995; 154: 1532. Link, Google Scholar 35 : Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res1999; 5: 257. Google Scholar 36 : Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol1997; 151: 1523. Google Scholar 37 : Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenic mechanisms. Clin Cancer Res2000; 6: 1936. Google Scholar 38 : Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell1993; 4: 121. Google Scholar 39 : In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis1995; 13: 407. Google Scholar 40 : The pathogenesis of cancer metastasis: relevance to biotherapy. In: Principles of Cancer Biotherapy. Edited by . Boston: Kluwer1998: 16. chapt. 2. Google Scholar 41 : Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate1994; 24: 46. Google Scholar 42 : EGF stimulates the synthesis of cell-attachment proteins in human breast cancer cell line PMC42. Int J Cancer1987; 40: 207. Google Scholar 43 : Rapid effects of EGF on cytoskeletal structures and adhesive properties of highly metastatic rat mammary adenocarcinoma cells. Clin Exp Metastasis1993; 11: 113. Google Scholar 44 : Cell movement elicited by EGF-R requires kinase and autophosphorylation but is separable from mitogenesis. J Cell Biol1994; 124: 547. Google Scholar 45 : EGFR-mediated cell motility: phospholipase C activity is required, but MAP kinase activity is not sufficient for induced cell movement. J Cell Biol1994; 127: 847. Google Scholar 46 : Development of a novel human extracellular matrix for quantitation of the invasiveness of human cells. Cancer Lett1993; 69: 123. Google Scholar 47 : Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res2000; 6: 1. Google Scholar 48 : Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst1988; 80: 1605. Google Scholar 49 : A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res1991; 51: 4575. Google Scholar 50 : Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res1993; 53: 4637. Google Scholar 51 : Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts. Proc Annu Meet Am Assoc Cancer Res1994; 35: A2262. 380. Google Scholar 52 : Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res1999; 5: 909. Google Scholar 53 : In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res2000; 6: 701. Google Scholar 54 : Apoptosis and the cell cycle. J Cell Biochem1995; 58: 160. Google Scholar 55 : Induction of apoptosis in fibroblasts by c-myc protein. Cell1992; 69: 119. Google Scholar 56 : Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol2000; 18: 904. Google Scholar 57 : Phase I study of anti-epidermal growth factor receptor (EGFR) antibody C225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Annu Meet Am Soc Clin Oncol1998; 17: A1522. 395a. Google Scholar 58 : A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC). Proc Annu Meet Am Soc Clin Oncol1999; 18: A1502. 389a. Google Scholar 59 : Tyrosine kinase inhibition: an approach to drug development. Science1995; 267: 1782. Google Scholar 60 : A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science1994; 265: 1093. Google Scholar 61 : PD 153035, a tyrosine kinase inhibitor, prevents receptor activation and inhibits growth of cancer cells overexpressing the epidermal growth factor receptor in a dose and receptor number dependent manner. Clin Cancer Res1997; 3: 2099. Google Scholar 62 : Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res1997; 57: 4838. Google Scholar 63 : Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem2000; 275: 6987. Google Scholar 64 : ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, upregulates p27KIP1 inducing G1 arrest and enhancing the antitumor effect of interferon. Proc Annu Meet Am Assoc Cancer Res2000; 41: A4910. 773. Google Scholar 65 : Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci U S A1998; 95: 12022. Google Scholar 66 : Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem1999; 42: 1803. Google Scholar 67 : Intermittent oral Zd1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EgFR-TkI), shows evidence of good tolerability and activity: final results from a Phase I study. Proc Annu Meet Am Soc Clin Oncol2000; 19: 5E. 3a. Google Scholar 68 : Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst1997; 89: 341. Google Scholar From the University of Texas, M. D. Anderson Cancer Center, Houston, Texas© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKassouf W, Brown G, Black P, Fisher M, Inamoto T, Luongo T, Gallagher D, Bar-Eli M, McConkey D, Adam L and Dinney C (2018) Is Vascular Endothelial Growth Factor Modulation a Predictor of the Therapeutic Efficacy of Gefitinib for Bladder Cancer?Journal of Urology, VOL. 180, NO. 3, (1146-1153), Online publication date: 1-Sep-2008. Volume 165Issue 4April 2001Page: 1152-1157 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordstherapeuticsepidermal growth factorgrowth substancesMetricsAuthor Information JOHN MENDELSOHN Financial interest and/or other relationships with ImClone Systems and Bristol Myers Squibb. More articles by this author COLIN P.N. DINNEY Financial interest and/or other relationships with Bayer Pharmaceutical, Imclone Systems and Matrix Pharmaceutical. More articles by this author Expand All Advertisement PDF downloadLoading ...